pocketful logo
Lupin Ltd logo

Lupin Ltd

NSE: LUPIN BSE: 500257

₹2185.90

(2.65)%

Tue, 03 Feb 2026, 10:25 am

mtf coin illustrationMTF 5x

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    97270.20

  • Net Profit

    3306.26

  • P/B

    5.38

  • Sector P/E

    31.51

  • P/E

    28.20

  • EV/EBITDA

    17.31

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    16.31

  • ROCE (Industry)

    15.98

  • RONW (Industry)

    14.01

  • ROE

    21

  • ROCE

    20.88

  • Debt/Equity

    0.27

  • EPS (TTM)

    94.64

  • Dividend Yield

    0.56

  • Book Value

    429.63

  • Interest Cover

    14.62

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends after 3 years are expected to be well covered by earnings (6.1x coverage).
  • Lupin's earnings are expected to grow significantly at over 20% yearly.
  • Lupin's earnings growth is expected to exceed the India market average.
  • Lupin's earnings growth is expected to exceed the low risk savings rate of 7.2%.
thumbs up icon

Cons

  • The company is paying a dividend however it is incurring a loss.
  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Lupin's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Lupin's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Lupin is expected to increase but not above the 50% threshold in 2 years time.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters46.8946.9046.9046.9246.95
FII21.4920.4921.2521.4622.04
DII25.5826.5525.5625.4124.74
Public6.036.066.286.206.26
Government0.010.010.010.010.01

Read More

Technical Analysis

RSI

58.91

MACD

8.85

50 DMA

2118.41

200 DMA

2009.78

Support and Resistance

TypeR1R2R3PPS1S2S3
Classic2456.302303.602228.202150.902075.501998.201845.50
Fibonacci2303.602245.272209.232150.902092.572056.531998.20
Camarilla2194.792180.802166.802150.902138.802124.812110.81

Pivots Level: Classic

R3

+305.40

2456.30

R2

+152.70

2303.60

R1

+77.30

2228.20

2150.90
2150.90
Pivot Point
LTP: 2185.90

S1

-75.40

2075.50

S2

-152.70

1998.20

S3

-305.40

1845.50

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    2151.36

  • 20-EMA

    2147.57

  • 30-EMA

    2138.14

  • 50-EMA

    2115.03

  • 100-EMA

    2072.05

  • 200-EMA

    2032.87

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
06 Nov 2025board-meetingsQuarterly Results
14 Jul 2025agm
14 May 2025dividend₹12.00 Dividend /Share25 Jul 2025
09 Jul 2024agm
06 May 2024dividend₹8.00 Dividend /Share16 Jul 2024
04 Jul 2023agm
09 May 2023dividend₹4.00 Dividend /Share14 Jul 2023
05 Jul 2022agm
19 May 2022dividend₹4.00 Dividend /Share15 Jul 2022
15 Jul 2021agm

Read More

Peer Comparison

Lupin Ltd logo

Lupin Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Read More

About Lupin Ltd

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant presence in the Cardiovascular, Diabetology, Asthama, Pediatrics, Central Nervous System, Gastro- Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. The Company along with its subsidiaries has manufacturing locations spread across India, USA, Mexico and Brazil with trading and other incidental and related activities extending to the global markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1983

Headquarters

CEO

M D Gupta

Employees

Contact

Website icon

Website

https://www.lupin.com/

Email icon

Email

investorservices@lupinpharma.com

Phone icon

Phone

91-22-6640 2323

Location icon

Location

Kalpataru Inspire 3rd Floor, Off Western Exp HW Santacruz-E, Mumbai, Maharashtra, 400055

Read More

lupin ltd History

YearHistory
2020
  • Lupin's Pithampur facilities pass MHRA inspection.
  • Lupin launches generic arthritis relief tablet in the US.
  • Lupin receives EIR from US FDA for Florida inhalation research centre.
  • Lupin receives EIR from US FDA for Nagpur plant.
  • Lupin receives US FDA approval for generic product.
2021
  • Lupin receives US FDA approval for generic anti-fungal cream.
  • LupinLife launches ayurvedic energy supplement Be One.
  • Lupin launches Posaconazole delayed-release tablets.
  • Lupin launches generic Wilson's disease drug in the US.
  • Lupin launches generic diarrhea drug in the US.
2022
  • Lupin receives US FDA approval for Efinaconazole Topical Solution.
  • Lupin launches first reference laboratory in Kolkata.
  • Lupin receives US FDA approval for Vigabatrin for Oral Solution USP.
  • Lupin completes acquisition of brands from Anglo-French.
  • Lupin launches Merzee Capsules in the US.
2023
  • Lupin launches Softovac Liqui fibre liquid fibre product.
  • Lupin launches Turqoz (Norgestrel and Ethinyl Estradiol) Tablets USP in the US.
  • Lupin launches Rocuronium Bromide Injection in the US.
  • Lupin launches Diazepam Rectal Gel in the US.
  • Lupin agrees to acquire 5 drug brands from Menarini for Rs 101 crore.
2024
  • Lupin and Slurrp conclude Lupin Aptivate Achchi Bhookh Quiz.
  • Lupin acquires Huminsulin from Lilly to enhance diabetes portfolio.
  • Lupin receives US FDA approval for Emtricitabine and Tenofovir Alafenamide Tablets.
  • Lupin acquires 3 trademarks from Boehringer Ingelheim to strengthen diabetes portfolio.
  • Lupin's Pune R&D facility awarded LEED Platinum Certification.
  • Lupin launches Bumetanide Injection USP in the United States.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
No Result Found

Read More

lupin ltd. News

Lupin Launches Dasatinib Tablets in US Market

Lupin receives FDA approval and launches Dasatinib tablets in the US market across six dosage strengths, targeting expected annual sales of USD 930 million.

02 Feb 2026

stocks

Lupin Partners with TB Alliance for Tuberculosis Drug

Lupin forms strategic partnership with TB Alliance to develop Telacebec, a treatment for tuberculosis and other mycobacterial illnesses, providing manufacturing and regulatory support.

02 Feb 2026

stocks

DGTR Finds Dumping in Ethambutol Imports

India's trade regulator concludes preliminary dumping of Ethambutol Hydrochloride from China and Thailand, citing material injury to domestic pharmaceutical manufacturers including Lupin.

01 Feb 2026

stocks

Lupin Sees Rs. 19.17 Crore NSE Block Trade

Lupin Ltd. witnessed a significant block trade on NSE worth Rs. 19.17 crores involving approximately 90,749 shares at Rs. 2,112.70 per share, indicating substantial institutional activity.

29 Jan 2026

co actions results

Lupin Board Meeting Set for Feb 12 to Review Q3FY26

Lupin Limited has scheduled a board meeting on February 12, 2026, to consider and approve Q3FY26 unaudited financial results. Trading window closed from January 1, 2026.

28 Jan 2026

co actions results

Showing 1–5 of 59
Rows per page:

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800